Direct and indirect evidence for the reversibility of cirrhosis

被引:73
作者
Serpaggi, Jeanne
Carnot, Francoise
Nalpas, Bertrand
Canioni, Daniele
Guechot, Jerome
Lebray, Pascal
Vallet-Pichard, Anais
Fontaine, Helene
Bedossa, Pierre
Pot, Stanislas
机构
[1] Hop Necker Enfants Malad, Serv Hepatol, F-75014 Paris, France
[2] Hop Necker Enfants Malad, INSERM, U567, F-75014 Paris, France
[3] Hop Georges Pompidou, Serv Anat Pathol, F-75015 Paris, France
[4] Hop Necker Enfants Malad, Serv Anat Pathol, F-75015 Paris, France
[5] Hop St Antoine, Biochim Lab, F-75011 Paris, France
[6] Hop Kremlin Bicetre, Serv Anat Pathol, F-92110 Clichy, France
关键词
histopathologic improvement; specific treatment; cirrhosis; reversibility of cirrhosis;
D O I
10.1016/j.humpath.2006.07.007
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The aim of this study was to assess the reversibility of cirrhosis after therapy in a large series of patients with cirrhosis from various etiologies. We performed a retrospective study of 113 patients with biopsy-proven cirrhosis who underwent specific therapy and follow-up biopsies. Two pathologists performed blinded analyses of indirect biochemical and morphological signs of cirrhosis. Fourteen (12.4%) of the 113 cirrhotic patients had biopsy-proven disappearance of cirrhosis, defined as a decrease of 2 or greater in their METAVIR fibrosis score: 8 were related to hepatitis C virus, 3 to hepatitis B virus, and 3 to autoimmune cirrhosis. Necro-inflammatory activity decreased from 2.4 +/- 0.65 to 0.85 +/- 0.9 (P = .004), and fibrosis from 4 to 1.7 +/- 0.61 (P = .001). Prothrombin time (n = 1), platelet count (n = 2), serum albumin level (n = 2), and ultrasound abnormalities (n = 6) normalized in patients who had initial abnormalities. Hyaluronic acid and procollagen type III serum level decreased in all. In the 11 patients with regression of viral cirrhosis, 2 were nonresponders and 9 were responders, including 2 relapsers. The 3 patients with regressive autoimmune cirrhosis were complete responders to immunosupressive therapy. Using repeated liver biopsies, clinicobiochemical, radiologic, and endoscopic tests, we provide evidence for potential reversibility of cirrhosis after long-lasting suppression of the necro-inflammatory activity of liver disease. (c) 2006 Published by Elsevier Inc.
引用
收藏
页码:1519 / 1526
页数:8
相关论文
共 44 条
[1]  
ABDELAZIZ G, 1990, AM J PATHOL, V137, P1333
[2]   Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis [J].
Adinolfi, LE ;
Giordano, MG ;
Andreana, A ;
Tripodi, MF ;
Utili, R ;
Cesaro, G ;
Ragone, E ;
Mangoni, ED ;
Ruggiero, C .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (03) :590-595
[3]   Pathogenesis of liver fibrosis [J].
Alcolado, R ;
Arthur, MJP ;
Iredale, JP .
CLINICAL SCIENCE, 1997, 92 (02) :103-112
[4]   MATRIX DEGRADATION IN THE LIVER [J].
ARTHUR, MJP .
SEMINARS IN LIVER DISEASE, 1990, 10 (01) :47-55
[5]  
BEDOSSA P, 1994, HEPATOLOGY, V20, P15
[6]   THERAPY FOR HEPATIC-FIBROSIS [J].
BRENNER, DA ;
ALCORN, JM .
SEMINARS IN LIVER DISEASE, 1990, 10 (01) :75-83
[7]   Cholestasis-induced fibrosis is reduced by interferon α-2a and is associated with elevated liver metalloprotease activity [J].
Bueno, MR ;
Daneri, A ;
Armendáriz-Borunda, J .
JOURNAL OF HEPATOLOGY, 2000, 33 (06) :915-925
[8]   Reversibility of hepatic fibrosis in autoimmune hepatitis [J].
Dufour, JF ;
DeLellis, R ;
Kaplan, MM .
ANNALS OF INTERNAL MEDICINE, 1997, 127 (11) :981-985
[9]  
FALKMER S, 1970, Pediatrics, V45, P260
[10]   Long-term benefit of interferon a therapy of chronic hepatitis D: Regression of advanced hepatic fibrosis [J].
Farci, P ;
Roskams, T ;
Chessa, L ;
Peddis, G ;
Mazzoleni, AP ;
Scioscia, R ;
Serra, G ;
Lai, ME ;
Loy, M ;
Caruso, L ;
Desmet, V ;
Purcell, RH ;
Balestrieri, A .
GASTROENTEROLOGY, 2004, 126 (07) :1740-1749